

Mark Gurnell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/356842/publications.pdf>

Version: 2024-02-01

125
papers

8,272
citations

76326

40
h-index

49909

87
g-index

127
all docs

127
docs citations

127
times ranked

8286
citing authors

#	ARTICLE	IF	CITATIONS
1	Dominant negative mutations in human PPAR $\hat{3}$ associated with severe insulin resistance, diabetes mellitus and hypertension. <i>Nature</i> , 1999, 402, 880-883.	27.8	1,286
2	Human Metabolic Syndrome Resulting From Dominant-Negative Mutations in the Nuclear Receptor Peroxisome Proliferator-Activated Receptor- \hat{A} . <i>Diabetes</i> , 2003, 52, 910-917.	0.6	412
3	100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care – Preliminary Report. <i>New England Journal of Medicine</i> , 2021, 385, 1868-1880.	27.0	352
4	A Mutation in the Thyroid Hormone Receptor Alpha Gene. <i>New England Journal of Medicine</i> , 2012, 366, 243-249.	27.0	340
5	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	11.4	315
6	Second-to-fourth digit ratio predicts success among high-frequency financial traders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 623-628.	7.1	297
7	Mutations in the selenocysteine insertion sequence–binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. <i>Journal of Clinical Investigation</i> , 2010, 120, 4220-4235.	8.2	268
8	A Dominant-negative Peroxisome Proliferator-activated Receptor $\hat{3}$ (PPAR $\hat{3}$) Mutant Is a Constitutive Repressor and Inhibits PPAR $\hat{3}$ -mediated Adipogenesis. <i>Journal of Biological Chemistry</i> , 2000, 275, 5754-5759.	3.4	249
9	Pitfalls in the measurement and interpretation of thyroid function tests. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2013, 27, 745-762.	4.7	216
10	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e937-e946.	3.6	207
11	Evaluation of the Sensitivity and Specificity of ^{11}C -Metomidate Positron Emission Tomography (PET)-CT for Lateralizing Aldosterone Secretion by Conn's Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 100-109.	3.6	203
12	Cortisol shifts financial risk preferences. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3608-3613.	7.1	200
13	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. <i>European Journal of Endocrinology</i> , 2018, 178, 265-276.	3.7	196
14	Multidisciplinary management of acromegaly: A consensus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 667-678.	5.7	183
15	Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4146-4154.	3.6	176
16	The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor $\hat{3}$ and Its Therapeutic Modulation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2412-2421.	3.6	167
17	Non-DNA binding, dominant-negative, human PPAR $\hat{3}$ mutations cause lipodystrophic insulin resistance. <i>Cell Metabolism</i> , 2006, 4, 303-311.	16.2	164
18	Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. <i>Clinical Endocrinology</i> , 2016, 84, 799-808.	2.4	149

#	ARTICLE	IF	CITATIONS
19	Digenic inheritance of severe insulin resistance in a human pedigree. <i>Nature Genetics</i> , 2002, 31, 379-384.	21.4	134
20	A role for helix 3 of the TR β ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone. <i>EMBO Journal</i> , 1998, 17, 4760-4770.	7.8	130
21	Elevated Plasma Adiponectin in Humans with Genetically Defective Insulin Receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3219-3223.	3.6	127
22	Pregnancy, Primary Aldosteronism, and Adrenal <i>CTNNB1</i> Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 1429-1436.	27.0	123
23	A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1040-1050.	3.6	120
24	An Adult Female With Resistance to Thyroid Hormone Mediated by Defective Thyroid Hormone Receptor β . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4254-4261.	3.6	116
25	Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR) β 1 and TR β 2: clinical, biochemical, and genetic analyses of three related patients. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 619-626.	11.4	100
26	Functional implications of genetic variation in human PPAR β . <i>Trends in Endocrinology and Metabolism</i> , 2009, 20, 380-387.	7.1	88
27	Interoceptive Ability Predicts Survival on a London Trading Floor. <i>Scientific Reports</i> , 2016, 6, 32986.	3.3	79
28	PPAR β and metabolism: insights from the study of human genetic variants. <i>Clinical Endocrinology</i> , 2003, 59, 267-277.	2.4	78
29	Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 47-58.	10.7	74
30	A role for 11C-methionine PET imaging in ACTH-dependent Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2015, 173, M107-M120.	3.7	73
31	Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 871-881.	5.6	65
32	Peroxisome proliferator-activated receptor β and the regulation of adipocyte function: lessons from human genetic studies. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2005, 19, 501-523.	4.7	64
33	What should be done when thyroid function tests do not make sense?. <i>Clinical Endocrinology</i> , 2011, 74, 673-678.	2.4	62
34	Cardiovascular Disease and Sleep-Disordered Breathing in Acromegaly. <i>Neuroendocrinology</i> , 2016, 103, 75-85.	2.5	57
35	Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. <i>Pituitary</i> , 2012, 15, 276-287.	2.9	54
36	Modern imaging of pituitary adenomas. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101278.	4.7	54

#	ARTICLE	IF	CITATIONS
37	Low DHEAS: A Sensitive and Specific Test for Detection of Subclinical Hypercortisolism in Adrenal Incidentalomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2718.	3.6	50
38	¹¹ C-Metomidate PET/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice. <i>Clinical Endocrinology</i> , 2019, 90, 670-679.	2.4	49
39	Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective. <i>Pituitary</i> , 2020, 23, 327-337.	2.9	49
40	The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative pheochromocytoma. <i>European Journal of Endocrinology</i> , 2007, 157, 533-537.	3.7	42
41	Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI. <i>European Journal of Endocrinology</i> , 2016, 175, 485-498.	3.7	41
42	Reversible Pituitary Enlargement in the Syndrome of Resistance to Thyroid Hormone. <i>Thyroid</i> , 1998, 8, 679-682.	4.5	37
43	Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. <i>Nature Genetics</i> , 2021, 53, 1360-1372.	21.4	37
44	Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. <i>ERJ Open Research</i> , 2019, 5, 00009-2019.	2.6	36
45	Nuclear imaging in the diagnosis of primary aldosteronism. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 150-156.	2.3	34
46	Is there an optimal preoperative management strategy for pheochromocytoma/paraganglioma?. <i>Clinical Endocrinology</i> , 2017, 86, 163-167.	2.4	33
47	Comparing single-best-answer and very-short-answer questions for the assessment of applied medical knowledge in 20 UK medical schools: Cross-sectional study. <i>BMJ Open</i> , 2019, 9, e032550.	1.9	31
48	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa205.	0.2	31
49	Maternal Isodisomy for Chromosome 9 Causing Homozygosity for a Novel FOXE1 Mutation in Syndromic Congenital Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4031-4036.	3.6	28
50	A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly. <i>Clinical Endocrinology</i> , 2013, 78, 424-430.	2.4	28
51	How to interpret thyroid function tests. <i>Clinical Medicine</i> , 2013, 13, 282-286.	1.9	28
52	A Novel Albumin Gene Mutation (R222I) in Familial Dysalbuminemic Hyperthyroxinemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1381-E1386.	3.6	28
53	Familial Adrenocortical Carcinoma in Association With Lynch Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2269-2272.	3.6	27
54	A Novel Thyrotropin-Releasing Hormone Receptor Missense Mutation (P81R) in Central Congenital Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 847-851.	3.6	25

#	ARTICLE	IF	CITATIONS
55	Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection. <i>Pituitary</i> , 2021, 24, 839-853.	2.9	24
56	Localisation of an occult thyrotropinoma with 11 C-methionine PET-CT before and after somatostatin analogue therapy. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 1050.	11.4	23
57	Clinical prevalence and outcome impact of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a systematic review with meta-analysis. <i>Pituitary</i> , 2016, 19, 522-535.	2.9	23
58	“Striking the Right Balance” in Targeting PPAR β in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. <i>PPAR Research</i> , 2007, 2007, 1-14.	2.4	22
59	IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e70-e84.	3.6	22
60	A safe approach to surgery for pituitary and skull base lesions during the COVID-19 pandemic. <i>Acta Neurochirurgica</i> , 2020, 162, 1509-1511.	1.7	22
61	Targeted Molecular Imaging in Adrenal Disease—An Emerging Role for Metomidate PET-CT. <i>Diagnostics</i> , 2016, 6, 42.	2.6	21
62	Time Dependence of Radiation-induced Hypothalamic–Pituitary Axis Dysfunction in Adults Treated for Non-pituitary, Intracranial Neoplasms. <i>Clinical Oncology</i> , 2017, 29, 34-41.	1.4	21
63	Advances in the Imaging of Pituitary Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 357-373.	3.2	20
64	Nephrogenic syndrome of inappropriate antidiuresis secondary to an activating mutation in the arginine vasopressin receptor AVPR2. <i>Clinical Endocrinology</i> , 2016, 85, 306-312.	2.4	19
65	Physiological and Pathological Roles in Human Adrenal of the Glomeruli-Defining Matrix Protein NPNT (Nephronectin). <i>Hypertension</i> , 2017, 69, 1207-1216.	2.7	19
66	Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab. <i>Seminars in Oncology</i> , 2018, 45, 151-155.	2.2	19
67	Nuclear receptors in disease: thyroid receptor beta, peroxisome-proliferator-activated receptor gamma and orphan receptors. <i>Essays in Biochemistry</i> , 2004, 40, 169-189.	4.7	19
68	PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly. <i>Neurosurgical Focus</i> , 2020, 48, E8.	2.3	19
69	Long-term corticosteroid use, adrenal insufficiency and the need for steroid-sparing treatment in adult severe asthma. <i>Journal of Internal Medicine</i> , 2021, 290, 240-256.	6.0	18
70	NEFM (Neurofilament Medium) Polypeptide, a Marker for Zona Glomerulosa Cells in Human Adrenal, Inhibits D1R (Dopamine D1 Receptor)-Mediated Secretion of Aldosterone. <i>Hypertension</i> , 2017, 70, 357-364.	2.7	17
71	Increased Prevalence of Gallbladder Polyps in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1120-E1125.	3.6	16
72	A novel IGSF1 mutation in a large Irish kindred highlights the need for familial screening in the IGSF1 deficiency syndrome. <i>Clinical Endocrinology</i> , 2018, 89, 813-823.	2.4	16

#	ARTICLE	IF	CITATIONS
73	New types of localization methods for adrenocorticotrophic hormone-dependent Cushing's syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101513.	4.7	16
74	Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance. Endocrine, 2016, 54, 778-787.	2.3	15
75	ANO4 (Anoctamin 4) Is a Novel Marker of Zona Glomerulosa That Regulates Stimulated Aldosterone Secretion. Hypertension, 2019, 74, 1152-1159.	2.7	15
76	Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC. Endocrine-Related Cancer, 2020, 27, 361-373.	3.1	15
77	Familial dysalbuminaemic hyperthyroxinaemia interferes with current free thyroid hormone immunoassay methods. European Journal of Endocrinology, 2020, 182, 533-538.	3.7	14
78	Variation in passing standards for graduation-level knowledge items at UK medical schools. Medical Education, 2017, 51, 612-620.	2.1	13
79	Methods of 3D printing models of pituitary tumors. 3D Printing in Medicine, 2021, 7, 24.	3.1	12
80	Needle(s) in the Haystack" Synchronous Multifocal Tumor-Induced Osteomalacia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 390-393.	3.6	11
81	¹¹ C-metomidate PET-CT scanning can identify aldosterone-producing adenomas after unsuccessful lateralisation with CT/MRI and adrenal venous sampling. Journal of Human Hypertension, 2017, 31, 483-484.	2.2	11
82	Applying physical science techniques and CERN technology to an unsolved problem in radiation treatment for cancer: the multidisciplinary 'VoxTox' research programme. CERN IdeaSquare Journal of Experimental Innovation, 2017, 1, 3-12.	2.0	11
83	Combining field work and laboratory work in the study of financial risk-taking. Hormones and Behavior, 2017, 92, 13-19.	2.1	10
84	Clinical Evaluation of ¹¹ C-Met-Avid Pituitary Lesions Using a ZTE-Based AC Method. IEEE Transactions on Radiation and Plasma Medical Sciences, 2019, 3, 504-508.	3.7	10
85	Thinking differently " Students' cognitive processes when answering two different formats of written question. Medical Teacher, 2021, 43, 1-8.	1.8	10
86	Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas. Journal of Nuclear Medicine, 2021, 62, 575-625.	5.0	10
87	Modern imaging in Cushing's disease. Pituitary, 2022, 25, 709-712.	2.9	10
88	Identification and characterization of a novel de novo mutation (L346V) in the thyroid hormone receptor beta gene in a family with generalized thyroid hormone resistance. European Journal of Endocrinology, 1997, 137, 370-376.	3.7	9
89	Three Novel Mutations at Serine 314 in the Thyroid Hormone ¹²⁵ I Receptor Differentially Impair Ligand Binding in the Syndrome of Resistance to Thyroid Hormone. Endocrinology, 1999, 140, 5901-5906.	2.8	9
90	3D printing ¹⁸ F radioactive phantoms for PET imaging. EJNMMI Physics, 2021, 8, 38.	2.7	9

#	ARTICLE	IF	CITATIONS
91	Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. <i>Pituitary</i> , 2022, 25, 587-601.	2.9	9
92	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. <i>Pituitary</i> , 2022, 25, 64-73.	2.9	7
93	Resistance to Thyroid Hormone. , 2010, , 1745-1759.		7
94	11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy. <i>Pituitary</i> , 2022, 25, 573-586.	2.9	7
95	The use of ¹¹ carbon methionine positron emission tomography (PET) imaging to enhance radiotherapy planning in the treatment of a giant, invasive pituitary adenoma. <i>BJR case Reports</i> , 2017, 3, 20160098.	0.2	6
96	Gestational pituitary apoplexy. <i>Indian Journal of Endocrinology and Metabolism</i> , 2017, 21, 484.	0.4	6
97	Adult female with symptomatic AVPR2-related nephrogenic syndrome of inappropriate antidiuresis (NSIAD). <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.5	5
98	Long-term oncological outcomes after haemorrhagic apoplexy in pituitary adenoma managed operatively and non-operatively. <i>Acta Neurochirurgica</i> , 2022, 164, 1115.	1.7	5
99	An approach to a patient with primary hyperparathyroidism and a suspected ectopic parathyroid adenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	3.6	4
100	Localization of TSH-secreting pituitary adenoma using 11C-methionine image subtraction. <i>EJNMMI Research</i> , 2022, 12, 26.	2.5	4
101	Acromegaly and Cushing's syndrome caused by a neuroendocrine tumor arising within a sacrococcygeal teratoma. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 1768-1771.	0.5	3
102	Hyperthyroxinemia and Hypercortisolemia due to Familial Dysalbuminemia. <i>Thyroid</i> , 2020, 30, 1681-1684.	4.5	3
103	A remarkable case of thyrotoxicosis initially caused by gravesâ€™ disease followed by a probable TSHoma â€” a case report. <i>BMC Endocrine Disorders</i> , 2020, 20, 133.	2.2	3
104	The influence of candidatesâ€™ physical attributes on assessorsâ€™ ratings in clinical practice. <i>Medical Teacher</i> , 2021, 43, 554-559.	1.8	3
105	Wilson Disease: Never Too Late . . . <i>American Journal of Medicine</i> , 2022, 135, e370-e371.	1.5	3
106	More than just morning sickness. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 1123-1125.	0.5	2
107	Order effects in high stakes undergraduate examinations: an analysis of 5â€¦years of administrative data in one UK medical school. <i>BMJ Open</i> , 2016, 6, e012541.	1.9	2
108	National inter-rater agreement of standardised simulated-patient-based assessments. <i>Medical Teacher</i> , 2021, 43, 341-346.	1.8	2

#	ARTICLE	IF	CITATIONS
109	AST to ALT Ratio and Peripheral Arterial Disease in a Hypertensive Population“Is There a Link?. Angiology, 2021, 72, 905-907.	1.8	2
110	Using very short answer errors to guide teaching. Clinical Teacher, 2022, , .	0.8	2
111	Hypotension, polyuria and a cardiac arrest. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 437-438.	0.5	1
112	Functional imaging. , 2021, , 103-113.		1
113	Extended TSS (guided by 11C-methionine PET + MRI (Met-PET/MRCR)) can be an effective treatment option for patients with persistent acromegaly due to previously deemed unresectable lateral disease. Endocrine Abstracts, 0, , .	0.0	1
114	Ablation Treatment Planning for Patients with Primary Aldosteronism. , 2022, , .		1
115	Molecular Characterisation of Dominant Negative Mutations in Human Ppar ³ . Clinical Science, 2002, 102, 1P-1P.	0.0	0
116	Hypopituitarism, pulmonary infiltration and a spontaneously resolving occipital mass. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 147-149.	0.5	0
117	EP-1129: Pre and post-irradiation hypothalamic-pituitary axis dysfunction in adults treated for brain tumours. Radiotherapy and Oncology, 2016, 119, S541.	0.6	0
118	Reduction in Total Radiation Exposure Using X-ray Image Guidance Illustrated in a Patient Receiving Pituitary Radiotherapy. Clinical Oncology, 2018, 30, 199-200.	1.4	0
119	Oncogenic osteomalacia. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 421-422.	0.5	0
120	A journal for the modern era. Endocrinology, Diabetes and Metabolism, 2018, 1, e00001.	2.4	0
121	Response to Letter to the Editor: “GDF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction” Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2315-e2316.	3.6	0
122	TSH-Secreting Pituitary Adenomas. , 2018, , 261-266.		0
123	Black urine“alkaptonuria. QJM - Monthly Journal of the Association of Physicians, 2022, , .	0.5	0
124	Persistent Reductions in OCS Use in Patients with Severe, OCS-Dependent Asthma Treated with Dupilumab: LIBERTY ASTHMA TRAVERSE Study. , 2022, , .		0
125	The influence of candidatesâ€™ physical attributes on patient ratings in simulated assessments of clinical practice. Medical Teacher, 0, , 1-6.	1.8	0